|
Active substance |
Zanubrutinib |
|
Holder |
BeiGene Belgium SRL |
|
Status |
Running |
|
Indication |
monotherapy to adult patients with relapsing or refractory Mantle Cell Lymphoma (MCL) who have received at least 1 prior therapy. |
|
Public documents |
|
|
Last update |
30/09/2024 |
Brukinsa
Last updated on 07/11/2024